Systemic Therapy for Gallbladder Cancer

Overview

Journal Chin Clin Oncol

Publisher AME Publishing Company

Specialty Oncology

Date 2019 Sep 6

PMID 31484490

Citations 21

Authors

Milind Javle

Haitao Zhao

Ghassan K Abou-Alfa

Affiliations

Soon will be listed here.

Abstract

Gallbladder cancer is an aggressive cancer that continues to be an important health care issue in certain regions of the world such as Southeast Asia and Latin America. Most patients are diagnosed at an advanced, unresectable stage and systemic therapy is their only option. Gallbladder cancer patients have traditionally been included in clinical trials for biliary tract cancer. Thus, systemic chemotherapy options for this cancer are similar to those for cholangiocarcinoma, including gemcitabine and cisplatin in the first line and FOLFOX in the second-line setting. Ongoing phase III clinical trials may change the systemic therapy paradigm for this cancer. Molecular profiling has indicated important genetic differences between gallbladder cancer and cholangio-carcinoma, which affects choice of targeted therapy. Her2/neu amplification, PIK3CA mutations and DNA repair genetic aberrations are relatively frequent and represent actionable targets for this cancer.

Citing Articles

Detecting the preoperative peripheral blood systemic immune-inflammation index (SII) as a tool for early diagnosis and prognosis of gallbladder cancer.

Liu F, Yin P, Jiao B, Shi Z, Qiao F, Xu J BMC Immunol. 2025; 26(1):7.

PMID: 39966731 PMC: 11834489. DOI: 10.1186/s12865-025-00683-x.

Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder.

Widiasi E, Zaky Romadhon P, Ashariati A, Bintoro S, Noor Diansyah M, Ayu Amrita P J Blood Med. 2024; 15:523-531.

PMID: 39717674 PMC: 11665135. DOI: 10.2147/JBM.S482753.

KLF5 silencing restrains proliferation, invasion, migration and angiogenesis of gallbladder carcinoma cells by transcriptional regulation of PDGFA.

Lu X, Hu K, Zhang D, Yin X, Nie J, Zhao K J Cancer Res Clin Oncol. 2024; 151(1):11.

PMID: 39704786 PMC: 11662046. DOI: 10.1007/s00432-024-06059-9.

Comparison of treatment models for single primary advanced gallbladder cancer.

Li R, Chen X, Wang B, Ai B, Min F, Cao D Front Immunol. 2024; 15:1500091.

PMID: 39606221 PMC: 11599203. DOI: 10.3389/fimmu.2024.1500091.

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target.

Qiang J, Zhao C, Shi L, Sun S, Wang H, Liu S Gene Ther. 2024; 31(11-12):594-606.

PMID: 39306629 PMC: 11576511. DOI: 10.1038/s41434-024-00488-4.

References

DHondt M, Lapointe R, Benamira Z, Pottel H, Plasse M, Letourneau R . Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. Eur J Surg Oncol. 2013; 39(6):548-53. DOI: 10.1016/j.ejso.2013.02.010. View

Lazcano-Ponce E, Miquel J, Munoz N, Herrero R, Ferrecio C, Wistuba I . Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2002; 51(6):349-64. DOI: 10.3322/canjclin.51.6.349. View

Geynisman D, Catenacci D . Toward personalized treatment of advanced biliary tract cancers. Discov Med. 2012; 14(74):41-57. View

Lamarca A, Barriuso J, McNamara M, Valle J . Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treat Rev. 2018; 70:168-177. DOI: 10.1016/j.ctrv.2018.09.002. View

Jain A, Javle M . Molecular profiling of biliary tract cancer: a target rich disease. J Gastrointest Oncol. 2016; 7(5):797-803. PMC: 5056250. DOI: 10.21037/jgo.2016.09.01. View

Shroff R, Javle M, Xiao L, Kaseb A, Varadhachary G, Wolff R . Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 5(6):824-830. PMC: 6567834. DOI: 10.1001/jamaoncol.2019.0270. View

Jain A, Kwong L, Javle M . Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016; 17(11):58. DOI: 10.1007/s11864-016-0432-2. View

Javle M, Churi C, Kang H, Shroff R, Janku F, Surapaneni R . HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015; 8:58. PMC: 4469402. DOI: 10.1186/s13045-015-0155-z. View

Phelip J, Edeline J, Blanc J, Barbier E, Michel P, Bourgeois V . Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2018; 51(2):318-320. DOI: 10.1016/j.dld.2018.11.018. View

10.

Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X . Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 2020; 8(6):604-614. PMC: 6943012. DOI: 10.21037/hbsn.2019.04.11. View

11.

Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M . Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res. 2014; 7(2):42-8. PMC: 4007675. View

12.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley R, Wang K . Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016; 122(24):3838-3847. DOI: 10.1002/cncr.30254. View

13.

Lamarca A, Hubner R, Ryder W, Valle J . Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014; 25(12):2328-2338. DOI: 10.1093/annonc/mdu162. View

14.

Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic A . Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014; 45(4):701-8. PMC: 4428571. DOI: 10.1016/j.humpath.2013.11.001. View

15.

Lowery M, Ptashkin R, Jordan E, Berger M, Zehir A, Capanu M . Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin Cancer Res. 2018; 24(17):4154-4161. PMC: 6642361. DOI: 10.1158/1078-0432.CCR-18-0078. View

16.

Yamashita S, Koay E, Passot G, Shroff R, Raghav K, Conrad C . Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2016; 123(8):1354-1362. PMC: 5384875. DOI: 10.1002/cncr.30488. View

17.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

18.

Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S . Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4(8):611-621. DOI: 10.1016/S2468-1253(19)30086-X. View